03Recent Activity
Invested in Breye Therapeutics to advance oral treatments for retinal diseases.
SEP 29, 2026
Participated as an existing syndicate member in Breye Therapeutics' EUR 67.5M Series A.
SEP 29, 2026
Breye Therapeutics is focused on developing orally administered therapies for patients with deteriorating vision from retinal vascular diseases, particularly diabetic retinopathy and age-related macular degeneration
Breye Therapeutics is focused on developing orally administered therapies for patients with deteriorating vision from retinal vascular diseases, particularly diabetic retinopathy and age-related macular degeneration.